Invega

J & J reported global Invega sales of $424 million for 2010.

J Peter Loftus 2011

Invega Sustenna is an injectable formulation of Invega that can be administered monthly for treatment of schizophrenia.

J Peter Loftus 2011

J&J recently recalled about 70,000 syringes of Invega Sustenna after discovering cracks in the syringes that could potentially lead to infections or reduced efficacy in users.

J&J Scraps Antipsychotic Study Peter Loftus 2011

Invega Sustenna is a once-monthly injection intended for people who have difficulty remembering to take a pill every day; it was approved by U.S. regulators in 2009.

J&J Scraps Antipsychotic Study Peter Loftus 2011

Invega generated sales of $424 million for 2010, up 8% from 2009.

J&J Scraps Antipsychotic Study Peter Loftus 2011

Johnson & Johnson has scrapped plans for a clinical trial comparing its injectable antipsychotic Invega Sustenna with various oral treatments, citing a "reconsideration of priorities."

J&J Scraps Antipsychotic Study Peter Loftus 2011

Researchers had planned to test whether Invega Sustenna could delay time until treatment failure—defined as re-hospitalization, suicide, discontinuation of treatment and other events—versus the other drugs for a period up to 12 months.

J&J Scraps Antipsychotic Study Peter Loftus 2011

Joint replacement systems so painful they required corrective surgery were also recalled, as were contact lenses that irritated eyes, along with potentially contaminated syringes full of the anti-psychotic drug Invega.

J&J issues another recall, for epilepsy pills 2011

The study's aim had been to compare Invega Sustenna with several oral antipsychotics including J&J's own Risperdal and AstraZeneca PLC's Seroquel in 1,000 schizophrenia patients recently discharged from psychiatric hospitals.

J&J Scraps Antipsychotic Study Peter Loftus 2011

An orally administered pill formulation of Invega was approved for sale in 2006.

J&J Scraps Antipsychotic Study Peter Loftus 2011